as of 11-20-2026 3:59pm EST
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia (excluding South Korea), South Korea, and Other.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | ORLANDO |
| Market Cap: | 71.7M | IPO Year: | 2005 |
| Target Price: | $11.00 | AVG Volume (30 days): | 68.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.56 | EPS Growth: | -5.13 |
| 52 Week Low/High: | $4.30 - $12.94 | Next Earning Date: | 11-10-2026 |
| Revenue: | $58,435,000 | Revenue Growth: | 9.24% |
| Revenue Growth (this year): | 4.22% | Revenue Growth (next year): | 19.43% |
| P/E Ratio: | 8.38 | Index: | N/A |
| Free Cash Flow: | -14914000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
SEC 8-K filings with transcript text
Nov 10, 2026 · 100% conf.
1D
+4.13%
$4.96
Act: -0.65%
5D
+13.62%
$5.41
20D
+18.09%
$5.63
2 lnsr-ex99_1.htm
Exhibit 99.1
LENSAR® Reports Third Quarter 2026 Financial Results and Provides Business Update
10 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in Third Quarter 2026; Backlog of 12 ALLY Systems as of September 30, 2026
Third Quarter Recurring Revenue Grew 17% Year Over Year to $12.6 Million
Total Laser Installed Base Reaches 450 Systems; ALLY System Installed Base Expands 22% Year Over Year
ORLANDO, Fla. (Nov 10, 2026) - LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2026 and provided an update on key operational initiatives.
“In-line with the expectations we shared in August, our third quarter results reflected the typical summer seasonality during which surgical scheduling and purchasing decisions contribute to a more measured pace of activity, leading to a sequential decline from a very strong second quarter,” said Nick Curtis, President and CEO of LENSAR. “Total revenue declined 1% year-over-year due to lower system sales against a robust number of sold systems in the prior year period, which was partially offset by growth in both procedure volume and recurring revenue. We see the year-over-year growth in these two revenue indicators as clear evidence of the increasing strength of our operational foundation, which we plan to continue leveraging to drive sustainable growth over the long-term.”
“LENSAR was built on innovation, and that remains a fundamental aspect of how we intend to continue competing and gain further ground in the laser cataract surgery market,” continued Curtis. “Over the quarter, our ALLY installed base grew to approximately 225 systems, expanding our opportunity to support surgeons and generate recurring revenue through continued growth in procedure volumes. We remain focused on advancing the capabilities and adoption of our technology, deepening relationships with surgeon partners and distributors, and utilizing this growing installed base to drive success. While quarterly results may fluctuate due to the timing of system sales and placements, among other factors, our commitment to innovation and disciplined commercial execution remains unchanged.”
LENSAR Q3 2026 Financial Summary
Metric
% Change
Revenue
-1%
Recurring revenue
+17%
Procedure revenue
+17%
Procedure volume
52,545
46,811
+12%
Recurring revenue %
89%
75%
+14 pts
Total Laser Installed Base
450
425
+6%
Total ALLY Installed Base
225
185
+22%
Net Loss
N/M
Adjusted EBITDA
N/M
*N/M = Not meaningful Third Quarter 2026 Financial Results During the three months ended September 30, 2026, total revenue was $14.1 million, compared with $14.3 million in the prior year period. As disclosed in the Company’s second quarter operational update, the third quarter is typically the slowest of the year for cataract procedures and sales activity given extended holidays in various parts of the world and
summer vacations in the United States. Procedure volume was 52,545 in the third quarter, compared with 46,811 in the third quarter of 2025. Recurring revenue increased 17% year over year to $12.6 million and represented 89% of total revenue, compared with $10.8 million, or 75% of total revenue a year earlier.
The Company placed 10 ALLY Systems during the third quarter, bringing the total installed ALLY base to approximately 225 ALLY Systems at quarter end. The total installed base reached approximately 450 systems. As of September 30, 2026, the Company had a backlog of 12 ALLY Systems pending installation. The Company continues to prioritize differentiated technology and broader adoption of the ALLY System as it works to strengthen its recurring revenue base over time.
The following table provides information about revenue and recurring revenue, which we consider to be all components of our revenue except for the sales of our systems:
Three Months Ended September 30,
Nine Months Ended September 30,
(Dollars in thousands)
2026
2025
2026
2025
System
$
1,547
$
3,546
$
5,192
$
8,754
Recurring revenue:
Procedure
9,168
7,821
28,641
24,441
Lease
1,712
1,560
5,165
5,089
Service
1,704
1,389
5,056
4,126
Total recurring revenue
12,584
10,770
38,862
33,656
Total revenue
$
14,131
$
14,316
$
44,054
$
42,410
Recurring revenue %
89
%
75
%
88
%
79
%
The following table provides information about procedure volume:
2026
2025
2024
Q1
54,094
52,347
39,486
Q2
58,682
52,100
42,203
Q3
52,545
46,811
42,231
Total
165,321
151,258
123,920
Cash, cash equivalents, and investments totaled $12.6 million as of September 30, 2026, compared to $18.0 million at December 31, 2025.
Conference Call
LENSAR management will h
Aug 13, 2026 · 100% conf.
1D
-3.29%
$7.84
Act: +1.11%
5D
-8.37%
$7.43
Act: +4.07%
20D
-9.19%
$7.36
2 lnsr-ex99_1.htm
Exhibit 99.1
LENSAR® Reports Second Quarter 2026 Results and Provides Business Update
10 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in Second Quarter 2026; Backlog of 13 ALLY Systems as of June 30, 2026
Second Quarter Recurring Revenue was $13.7 million
Total Laser Installed Base Climbs to 445 Systems, Driven by 30% Growth in ALLY Placements
ORLANDO, Fla. (Aug 13, 2026) - LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2026 and provided an update on key operational initiatives.
“In all metrics we delivered a significant second quarter, highlighted by 18% total revenue growth and 20% recurring revenue growth over the second quarter of 2025, and our strongest Adjusted EBITDA performance to date along with positive Net Income. These results reflect the continued strength of our business model, increasing utilization across our installed base, and sustained demand for the ALLY System,” said Nick Curtis, President and CEO of LENSAR. “Importantly, procedure revenue grew 23% over the second quarter last year as surgeons continued to increase the number of procedures performed using ALLY, reinforcing our belief in the solid health of our underlying business in realizing the long-term potential of our recurring revenue model. The growth we achieved during the second quarter gives us continued confidence in the trajectory of the business. Our increasing installed base, expanding recurring revenue and healthy backlog of pending installations exiting the second quarter position us well as we continue executing on our commercial strategy, LENSAR maintains a sharp focus on driving long-term value for our shareholders, as well as our surgeon partners and the patients they serve.”
LENSAR Q2 2026 Financial Summary
Metric
% Change
Revenue
+18%
Recurring revenue
+20%
Procedure revenue
+23%
Procedure volume
58,682
52,100
+13%
Recurring revenue %
83%
82%
+1%
Total Laser Installed Base
445
410
+9%
Total ALLY Installed Base
215
165
+30%
Net Income (Loss)
N/M
Adjusted EBITDA
N/M
*N/M = Not meaningful due to change from a loss to positive earnings. Second Quarter 2026 Financial Results In addition to the revenue growth summarized above, during the three months ended June 30, 2026, the Company placed 10 ALLY Systems, bringing the total installed ALLY base to approximately 215 at quarter end. As of June 30, 2026, the Company had a backlog of 13 ALLY Systems pending installation.
The following table provides information about revenue and recurring revenue, which we consider to be all components of our revenue except for the sales of our systems:
Three Months Ended June 30,
Six Months Ended June 30,
(Dollars in thousands)
2026
2025
2026
2025
System
$
2,809
$
2,576
$
3,645
$
5,208
Recurring revenue:
Procedure
10,233
8,334
19,473
16,620
Lease
1,772
1,645
3,453
3,529
Service
1,681
1,380
3,352
2,737
Total recurring revenue
13,686
11,359
26,278
22,886
Total revenue
$
16,495
$
13,935
$
29,923
$
28,094
Recurring revenue %
83
%
82
%
88
%
81
%
The following table provides information about procedure volume:
2026
2025
2024
Q1
54,094
52,347
39,486
Q2
58,682
52,100
42,203
Total
112,776
104,447
81,689
Net income and Adjusted EBITDA increased due to improved revenue, lower operating expenses, and a $1.1 million tariff refund. Net income growth was offset by lower non-cash income related to the change in fair value of warrant liabilities.
Cash, cash equivalents, and investments totaled $13.6 million as of June 30, 2026, compared to $18.0 million at December 31, 2025.
Conference Call
LENSAR management will host a conference call and live webcast to discuss the results and provide an update on the Company’s go-forward strategy today, August 13, 2026, at 8:30 a.m. ET.
To participate by telephone, please use this registration link. All participants must use the link to complete the online registration process in advance of the conference call. The live webcast can be accessed under “Events & Presentations” in the Investor Relations section of the company’s website at https://ir.lensar.com. The call and webcast replay will be available for 30 days.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System® as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and proprietary imaging and software. ALLY is designed to transform premium cat
May 8, 2026 · 100% conf.
1D
-3.75%
$5.46
Act: +1.80%
5D
-8.96%
$5.17
Act: -1.90%
20D
-9.90%
$5.12
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.c706d217.1784333226.cc867905
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
See how LNSR stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "LNSR LENSAR Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.